The Pheo Para Alliance announced that PRRT trials for pheo/para patients have begun at the National Cancer Institute, a division of the National Institutes of Health in Washington, D.C. More information on this important clinical trial can be found here. The alliance,...

Unicorn Foundation New Zeleand happily announced on 21 November 2017 that they got the result from the Consumer Submission which was made earlier in August to Pharmac, the New Zealand government agency that decides which pharmaceuticals to publicly fund in New...

Unicorn Foundation New Zealand and eight more cancer local organizations presented a manifesto to the Minister of Health, politicians and their health advisors in a campaign to encourage all political parties to work with the NGOS to help Kiwis receive improved cancer...

CNETS India team is happy to share that two nuclear medicine centres in India have started Alpha PRRT for NET patients. World over, many clinical trials have established the benefit of PRRT for metastatic NETs. Alpha PRRT uses the more powerful alpha particle...

Since March 2017, Belgium now has a second Center of Excellence, reported NET&MEN kanker België vzw, the Belgian association for NET and MEN patients. After the university hospital of Leuven, now also the University Hospital of Antwerp has been rewarded with this...

INCA Strongly Supports the NET Community in the UK in its efforts to access to PRRT INCA strongly supports the neuroendocrine (NET) cancer community in the United Kingdom in its efforts to alleviate the devastating side effect of removing an outstanding, life...